Table 4.

Comparison of Predicted GMC and Seroprotection Rates based on 5-year and 11-year follow up periods

	Healive group				Havrix group
	Predicted GMC, mIU/mL (95%CI)		Predicted SR% (95%CI)		Predicted GMC, mIU/mL (95%CI)		Predicted SR% (95%CI)
M	5- year	11- year	5- year	11- year	5- year	11- year	5- year	11- year
126	138.2(116.4–164.2)		91.0(87.0–94.1)		92.4(66.8–128)		87.0(78.1,93.1)
186	67.6(53.2–85.8)	117.3(104.2–132.1)	73.4(67.8–78.5)	96.7%(94.4,98.9)	44.1(27.9–69.6)	95.6(76.8–119)	67.4(56.8,76.8)	92.7%(87.1,98.3)
246	33.0(24.3–45)	74.2(64.8–84.9)	57.9(51.9–63.8)	88.3%(84.3,92.4)	21.0(11.6–38)	63.8(49.6–82.1)	44.6(34.2,55.3)	84.1%(76.2,92.1)
306	16.1(11–23.6)	46.9(40.2–54.7)	45.3(39.3–51.4)	77.9%(72.7,83.2)	10.0(4.8–20.8)	42.6(31.9–56.9)	34.8(25.2,45.4)	73.2%(63.6,82.8)
366		29.6(24.9–35.3)		64.6%(58.5,70.6)		28.5(20.5–39.5)		59.8%(49.1,70.4)
426		18.7(15.4–22.8)		50.0%(43.7,56.3)		19(13.1–27.5)		43.9%(33.2,54.6)

M, Month; 5- year, based on 5- year follow up; 11- year, based on 11- year follow up.